Global Immune Globulin Subcutaneous (SCIG) Market

Projected to Reach USD 16.85 Billion by 2036, Fuelled by Rising Immunodeficiency

Prevalence, Home-Based Therapy Adoption, and Expanding Global Patient Access

Chem Reports has published its comprehensive market intelligence study, Global Immune Globulin Subcutaneous (SCIG) Market Outlook 2025–2036. The report reveals that the global SCIG market was valued at approximately USD 8.74 billion in 2025 and is projected to reach USD 16.85 billion by 2036, advancing at a compound annual growth rate (CAGR) of 6.4% throughout the forecast period. Rising prevalence of primary immunodeficiency disorders, expanding diagnostic capabilities enabling earlier disease identification, growing adoption of home-based subcutaneous immunoglobulin therapy, and broadening clinical indications across autoimmune and neurological conditions collectively underpin robust multi-year market expansion.

Immune Globulin Subcutaneous (SCIG) refers to concentrated immunoglobulin preparations derived from pooled human plasma, formulated for subcutaneous administration. SCIG offers clinically equivalent immunoprotection to intravenous immunoglobulin (IVIg) with the added benefit of self-administration from the patient's home, reducing hospital visits, healthcare system burden, and treatment-related disruptions to daily life. These patient-centric advantages have driven a sustained structural shift in immunoglobulin therapy from intravenous to subcutaneous routes of administration across both established and emerging markets.

The SCIG market sits at the intersection of three powerful healthcare megatrends: the global burden of immune-mediated diseases continuing to rise, the accelerating shift toward patient-centric home-based biologics administration, and the expansion of plasma-derived medicinal product (PDMP) manufacturing capacity to address historically constrained supply. This report delivers a comprehensive, independent analysis of market structure, competitive dynamics, segment-level demand forecasts, and strategic recommendations for pharmaceutical manufacturers, investors, healthcare payers, and policy stakeholders.

Immune globulin subcutaneous preparations contain concentrated polyclonal immunoglobulin G (IgG) antibodies purified from large pools of human plasma donations. The manufacturing process involves cold ethanol fractionation followed by multiple purification, viral inactivation, and sterile filtration steps, yielding a product with IgG content typically ranging from 10% to 20% (100–200 g/L) formulated for subcutaneous delivery. SCIG is administered via small-volume, slow-rate infusions into subcutaneous tissue using portable pump systems or through rapid push techniques, enabling patients to self-administer therapy at home following appropriate training.

The clinical case for SCIG has strengthened considerably over the past decade. Multiple randomized controlled trials and extensive real-world evidence have established SCIG's non-inferiority to IVIg in maintaining serum IgG trough levels and preventing infections in primary immunodeficiency patients. More recent evidence supports SCIG use in secondary immunodeficiency, autoimmune neurological conditions including CIDP and multifocal motor neuropathy (MMN), and selected inflammatory conditions. The convenience, patient preference, and health system cost advantages of SCIG over IVIg are driving prescriber and patient adoption globally.

Supply constraints linked to plasma collection capacity have historically been a market-limiting factor. The COVID-19 pandemic severely disrupted plasma donation volumes in 2020–2021, creating transient supply shortfalls and highlighting the structural fragility of plasma-derived medicinal product supply chains. The industry response has included major investment in plasma collection centre networks, enhanced donor recruitment programs, and manufacturing capacity expansion—investments that are expected to progressively alleviate supply constraints through the forecast period.

4.1 By Product Formulation / Type

The SCIG market encompasses distinct product formulations differentiated by concentration, administration approach, and enabling technology:

High-Concentration SCIG (20%) and Hyaluronidase-Facilitated SCIG (fSCIG) are the two fastest-growing product types, collectively reshaping the market's formulation mix. The 20% concentration format significantly reduces infusion volumes and time—a key quality-of-life driver for patients managing chronic weekly therapy. fSCIG, administered via a co-formulated recombinant hyaluronidase that transiently increases subcutaneous tissue permeability, enables monthly dosing frequency comparable to IVIg infusion cycles, representing a paradigm-shifting product format that is accelerating the conversion of IVIg patients to subcutaneous therapy.

4.2 By Application / Therapeutic Indication

CIDP represents the most dynamically growing therapeutic indication, driven by recent regulatory approvals of SCIG specifically for CIDP maintenance therapy in the United States and Europe, and by the substantial and previously underpenetrated patient population. The CIDP market is being further activated by fSCIG products offering monthly dosing convenience. Secondary immunodeficiency is also growing as a proportion of overall demand, reflecting the rising volume of cancer patients receiving therapies that impair humoral immunity and require long-term immunoglobulin replacement.

4.3 By Patient Demographics

4.4 By Administration Setting

The SCIG market exhibits a pronounced geographic hierarchy, with North America and Europe accounting for the substantial majority of global revenue, reflecting differences in diagnostic infrastructure, reimbursement frameworks, plasma collection capacity, and healthcare system sophistication.

North America

North America represents the world's largest SCIG market, underpinned by the United States' world-leading plasma collection infrastructure, mature immunology specialist community, and well-established reimbursement frameworks covering SCIG therapy in both primary and secondary immunodeficiency and increasingly in neurological conditions including CIDP. The ongoing conversion of existing IVIg patients to subcutaneous therapy—estimated to be ongoing in 30–40% of eligible patients—remains a major incremental demand driver. Canada's publicly funded healthcare system has progressively expanded SCIG reimbursement coverage, adding to regional growth. fSCIG product launches in the United States are creating an additional growth catalyst by enabling transition of monthly IVIg patients to home-based subcutaneous dosing.

Europe

Europe is a mature but growing SCIG market, characterized by variability in reimbursement coverage and home therapy support infrastructure across national healthcare systems. Germany, France, Sweden, Denmark, and the United Kingdom lead in SCIG penetration, supported by well-organized patient advocacy communities and national immunoglobulin governance frameworks. Eastern European markets represent a growth frontier where PID diagnosis rates are expanding and reimbursement systems are progressively incorporating SCIG. The European market is benefiting from broader SCIG label extensions—particularly for CIDP—and from healthcare system incentives to transition appropriate patients from hospital-administered IVIg to cost-effective home SCIG therapy.

Asia-Pacific

Asia-Pacific is the highest-growth SCIG region globally. China represents the largest Asia-Pacific market by population potential, though current penetration remains low due to limited domestic plasma collection capacity, restricted imported plasma-derived product access, and developing immunologist specialist infrastructure. Japan and South Korea represent more mature markets with established reimbursement and growing home therapy programs. India's large undiagnosed immunodeficiency population is beginning to be addressed through expanding specialist networks and improving diagnostic access, while Australia and New Zealand operate well-functioning national immunoglobulin governance programs that are incrementally supporting SCIG adoption.

Latin America

Latin America's SCIG market is at an inflection point, with Brazil leading regional growth driven by improving PID diagnosis rates, expanding specialist immunology networks, and progressive inclusion of SCIG in public health system coverage for eligible patients. Regional plasma collection infrastructure remains limited relative to demand, creating ongoing dependency on imported plasma-derived products and supply cost challenges. Argentina, Colombia, and Mexico represent secondary markets with growing specialist communities and improving diagnostic infrastructure.

Middle East & Africa

The Middle East and Africa region represents the earliest-stage but fastest-growing SCIG market globally. Saudi Arabia and UAE are investing in rare disease diagnosis and treatment infrastructure as part of broader healthcare system development programs. Genetic primary immunodeficiency disorders have notably high prevalence in certain Middle Eastern populations due to consanguinity patterns, representing an important unmet clinical need. Sub-Saharan Africa faces the most significant access barriers, with plasma collection, cold chain logistics, and specialist availability all constraining near-term market development.

The global SCIG market is highly consolidated, with the top five plasma-derived medicinal product manufacturers accounting for approximately 85% of global SCIG revenue. This concentration reflects the extraordinary barriers to entry posed by plasma collection infrastructure requirements, manufacturing complexity, regulatory pathway length, and the scale of investment required to operate competitively in plasma fractionation. Competition is primarily non-price-based, focused on product differentiation by formulation, concentration, dosing convenience, and patient support services.

9.1 Accelerating Conversion from IVIg to SCIG

The ongoing structural transition of immunoglobulin therapy from intravenous to subcutaneous administration represents the most powerful internal market growth driver. Immunologists are increasingly initiating appropriate patients on SCIG as a first-line choice rather than IVIg, while a substantial existing IVIg patient population continues to be converted to subcutaneous therapy as clinical experience and patient support infrastructure matures. The advent of fSCIG products—enabling monthly dosing frequency equivalent to IVIg—has significantly expanded the pool of IVIg patients for whom subcutaneous conversion is clinically and practically appropriate.

9.2 Hyaluronidase-Facilitated SCIG (fSCIG) Transforming Dosing Paradigms

Hyaluronidase-facilitated SCIG represents the most significant product innovation in the immunoglobulin space in the current decade. By co-administering recombinant human hyaluronidase (rHuPH20) with IgG, fSCIG enables the delivery of large immunoglobulin volumes through a single subcutaneous infusion site at monthly intervals. This monthly dosing frequency matches IVIg convenience while offering the home administration and patient autonomy advantages of standard SCIG. FDA approval of fSCIG for both PID and CIDP has opened these products to the substantial existing IVIg market, representing a transformational commercial opportunity for license holders.

9.3 Expanding CIDP and Neurological Indications

CIDP has emerged as the most dynamic growth indication for SCIG. The condition—characterized by progressive or relapsing weakness and sensory loss—affects a substantial patient population that has historically been managed with IVIg infusions. Regulatory approvals for SCIG in CIDP maintenance therapy in both the United States and Europe have created a significant new patient segment. Clinical evidence continues to accumulate supporting SCIG use in additional autoimmune neurological conditions, including multifocal motor neuropathy, stiff person syndrome spectrum disorders, and autoimmune encephalitis, each representing incremental market expansion opportunities.

9.4 Digital Health Integration and Connected Infusion Devices

The integration of digital health technologies into home SCIG therapy is improving patient outcomes and strengthening manufacturer-patient relationships. Smart infusion pumps with wireless connectivity, patient therapy management applications, and remote nurse monitoring platforms are enabling healthcare providers to support home therapy patients more effectively, identify adherence issues early, and document real-world outcomes. These connected therapy ecosystems also create valuable data assets and increase switching costs once patients are established on a specific manufacturer's device and support ecosystem.

9.5 Plasma Supply Chain Investment and Diversification

The COVID-19 pandemic-induced plasma supply disruption accelerated pre-existing industry investment in plasma collection infrastructure resilience. Leading fractionators have significantly expanded plasma collection centre networks in the United States and are developing collection programs in Europe, Australia, and select emerging markets. Several manufacturers are also investing in plasma yield optimization technologies—improving the efficiency of IgG extraction from each liter of plasma—as a complement to volume-based supply expansion. These investments are progressively improving supply security and are expected to reduce supply constraint risk through the forecast period.

9.6 Emerging Market Access Programs and Reimbursement Evolution

Deliberate market access programs targeting previously underserved patient populations in Asia-Pacific, Latin America, and the Middle East are expanding the global SCIG addressable market. Manufacturer-supported patient registry and diagnosis programs, partnerships with national public health systems, and growing engagement with health technology assessment bodies are improving SCIG formulary access and reimbursement conditions in markets that previously had limited or no coverage. These access investments represent a multi-year market development initiative with potentially large long-term revenue implications as patient populations are identified and therapy established.

10.1 Key Market Drivers

•       Rising global prevalence of primary immunodeficiency disorders combined with improving diagnostic capabilities, including newborn screening programs and genetic testing expansion, enabling earlier identification and treatment initiation in growing patient populations.

•       Structural shift from hospital-administered IVIg to home-based SCIG driven by patient preference for independence, healthcare system cost-efficiency imperatives, and clinical evidence supporting equivalent therapeutic outcomes.

•       Regulatory approvals and expanding clinical evidence base for SCIG in CIDP and additional autoimmune neurological indications substantially enlarging the eligible patient population beyond the original primary immunodeficiency core indication.

•       fSCIG product innovations enabling monthly dosing frequency equivalent to IVIg, removing a key barrier to subcutaneous conversion for the large existing population of monthly IVIg infusion patients.

•       Healthcare system cost-containment pressure in high-income markets actively incentivizing the transition from costly hospital-administered IVIg to more economical home-based SCIG where clinically appropriate.

•       Growing immunodeficiency burden associated with expanding oncology treatment volumes—including chemotherapy and targeted agents—and increasing transplant activity, driving secondary immunodeficiency SCIG demand.

•       Improving plasma supply chain capacity and reliability as the industry invests in collection network expansion and yield optimization technologies post-COVID supply disruption.

10.2 Key Market Challenges

•       Human plasma supply dependency creates inherent and unpredictable supply vulnerability; public health events, donor recruitment challenges, and plasma collection facility disruptions can cause acute product shortages with direct patient impact.

•       Exceptional capital intensity and regulatory complexity of plasma fractionation manufacturing limits new entrant competition but also constrains the pace at which existing manufacturers can expand capacity to meet growing demand.

•       High product cost relative to many therapeutic alternatives creates access barriers in cost-constrained healthcare systems and exposes the market to health technology assessment reimbursement restrictions in key markets.

•       Reimbursement fragmentation—with significant variation in SCIG coverage, patient eligibility criteria, and reimbursed pricing across national healthcare systems—creates market access complexity that increases commercial operating costs.

•       Emerging gene therapy approaches for primary immunodeficiency, while years from widespread adoption, represent a long-term structural threat to IgG replacement therapy demand in genetically correctable PID patients.

•       FcRn receptor antagonist therapies, which reduce endogenous IgG catabolism or target pathogenic IgG in autoimmune conditions, represent an evolving competitive threat in certain autoimmune indications currently served by SCIG.

The SCIG value chain is uniquely complex, characterized by dependency on human biological material and exceptional regulatory, manufacturing, and distribution requirements at every stage:

The COVID-19 pandemic created a profound and multi-dimensional impact on the SCIG market that continues to influence market structure and strategy through 2025. The most acute impact was the severe disruption to plasma donation volumes. Plasma collection centre closures, donor hesitancy, and movement restrictions during the 2020–2021 pandemic period caused global plasma collection volumes to decline by an estimated 20–25% in 2020, creating supply shortfalls that affected immunoglobulin product availability globally. Patients with life-sustaining immunoglobulin requirements faced supply rationing, dose reductions, and treatment delays in the most acute supply constraint periods.

Simultaneously, the shift to home-based healthcare during the pandemic—driven by patient reluctance to attend hospital infusion centers and healthcare system pressure to reduce inpatient volumes—accelerated the adoption of home SCIG therapy. Many IVIg patients who had been receiving hospital-administered infusions were supported to transition to home SCIG during the pandemic, providing a structural and sustained boost to SCIG market share that has been maintained post-pandemic as patients have recognized the quality-of-life benefits of home therapy.

The pandemic's longer-term legacy on the SCIG market includes sustained industry investment in plasma collection network resilience and redundancy, accelerated digital health and remote monitoring adoption in home therapy programs, and a heightened policy focus on secure domestic plasma-derived medicinal product supply chains in the United States, Europe, and select Asia-Pacific markets. These structural changes are generally supportive of SCIG market development and supply security through the forecast period.

For SCIG Manufacturers:

•       Accelerate fSCIG product development and launch programs to capture the substantial IVIg-to-SCIG conversion opportunity among monthly IVIg infusion patients, representing the largest near-term incremental revenue opportunity in the immunoglobulin market.

•       Invest strategically in plasma collection network expansion and donor retention programs to secure the biological raw material supply foundation required to support growing therapy volumes, treating plasma supply security as a core strategic asset.

•       Develop differentiated patient support ecosystems—incorporating connected infusion devices, digital monitoring platforms, and comprehensive homecare services—to strengthen patient retention, demonstrate real-world outcomes, and support reimbursement engagement.

•       Build dedicated market access capabilities in high-growth emerging markets including China, India, Brazil, and the Middle East, investing in local diagnosis programs, patient registry development, and healthcare system partnership to establish market presence ahead of full commercial scale.

•       Actively invest in real-world evidence generation across the expanding CIDP and autoimmune neurological indication landscape to strengthen reimbursement positioning and support further label extensions.

For Investors:

•       Prioritize exposure to SCIG market leaders with vertically integrated plasma collection networks, differentiated high-concentration and fSCIG product portfolios, and demonstrated reimbursement breadth in North American and European markets.

•       Monitor the CIDP indication expansion closely as the largest near-term incremental indication opportunity; companies with first-mover fSCIG CIDP approvals are positioned for above-market SCIG growth through the early forecast period.

•       Evaluate plasma collection infrastructure investments—including plasma center operators and plasmapheresis technology developers—as strategic beneficiaries of the sustained demand growth creating long-term plasma supply tightness.

•       Assess the competitive threat timeline from gene therapy and FcRn antagonists carefully for indications-specific portfolio positioning, while recognizing that the core IgG replacement indication in PID and the broad polyclonal mechanism of action provide durable long-term market protection.

For Healthcare Payers & Health Systems:

•       Develop structured SCIG transition programs for appropriate existing IVIg patients, supported by patient training investment and homecare service infrastructure, to capture the significant cost-efficiency benefits of home SCIG therapy relative to hospital-administered IVIg.

•       Invest in newborn screening and immunology specialist diagnostic capacity to reduce the diagnosis delays that deprive PID patients of timely therapy initiation and increase disease burden and treatment cost.

•       Engage proactively with SCIG manufacturers on real-world evidence requirements, registry participation, and outcomes-based contracting frameworks to improve pricing sustainability and demonstrate value-based reimbursement approaches.

For Policy Makers & Regulators:

•       Develop national plasma-derived medicinal product security strategies that include domestic plasma collection infrastructure investment, import security provisions, and emergency supply reserve frameworks, reducing vulnerability to the supply disruptions highlighted by the COVID-19 pandemic.

•       Harmonize ethical and regulatory frameworks for paid plasma donation to balance supply adequacy requirements with appropriate donor protection standards, recognizing that plasma supply security is a genuine public health imperative.

•       Support and accelerate SCIG reimbursement coverage decisions in markets with significant unmet need, recognizing that delayed access to immunoglobulin replacement therapy for PID and CIDP patients has measurable clinical and economic costs.

This report was developed through a comprehensive mixed-methods research process. Primary research comprised structured interviews with immunology and neurology specialists, plasma fractionation industry executives, patient advocacy representatives, health technology assessment professionals, and market access leaders across the SCIG value chain in North America, Europe, and Asia-Pacific. Secondary research encompassed analysis of regulatory agency approval databases, clinical trial registries, plasma industry association publications, national immunoglobulin governance framework documentation, and proprietary pharmaceutical market databases. Market sizing employed a bottom-up indication-level patient population modeling methodology, combining epidemiological data with diagnosis, treatment, and SCIG penetration rate assumptions, validated against top-down revenue analysis across major market participants. All market values are expressed in nominal USD terms and represent Chem Reports' independent analytical judgment.

— END OF PRESS RELEASE —